|
Male, gender, n(%)
|
45 (75.0)
|
19 (73.1)
|
0.851*
|
|
Age, years, x ± s
|
61.8 ± 10.7
|
62.6 ± 11.1
|
0.760§
|
|
Current or former smokers, n(%)
|
31 (51.7)
|
17 (65.4)
|
0.239*
|
|
Histology, n(%)
| | |
0.297*
|
|
Adenocarcinoma
|
25 (41.7)
|
14 (53.8)
| |
|
Squamous carcinoma
|
35 (58.3)
|
12 (46.2)
| |
|
Disease stage, n(%)
| | |
0.274*
|
|
Stage III
|
26 (43.3)
|
8 (30.8)
| |
|
Stage IV
|
34 (56.7)
|
18 (69.2)
| |
|
Lines of therapy, n (%)
| | |
0.759*
|
|
<2
|
21 (35.0)
|
10 (38.5)
| |
|
≥ 2
|
39 (65.0)
|
16 (61.5)
| |
|
Therapeutic intervention, n(%)
| | |
0.343*
|
|
Chemotherapy+Immunotherapy
|
31 (51.7)
|
10 (38.5)
| |
|
Chemotherapy
|
21 (35.0)
|
9 (34.6)
| |
|
Immunotherapy
|
5 (8.3)
|
3 (11.5)
| |
|
Target therapy
|
3 (5.0)
|
4 (15.4)
| |
|
No. of metastatic organs, n(%)
| | |
1.000*
|
|
<2
|
30 (50.0)
|
13 (50.0)
| |
|
≥ 2
|
30 (50.0)
|
13 (50.0)
| |
|
No. of metastatic lymph nodes, n(%)
| | |
0.773*
|
|
<2
|
18 (30.0)
|
7 (26.9)
| |
|
≥ 2
|
42 (70.0)
|
19 (73.1)
| |
|
KPS score, n(%)
| | |
0.733*
|
|
90
|
54 (90.0)
|
22 (84.6)
| |
|
80
|
4 (6.7)
|
2 (7.7)
| |
|
70
|
2 (3.3)
|
2 (7.7)
| |
|
Laboratory indices at baseline, median(IQR)
| | | |
|
Neutrophils, ×109/L
|
3.61 [2.70,4.50]
|
3.62 [2.87,4.63]
|
0.929#
|
|
Platelets, ×109/L
|
205 [154,258]
|
200 [144,265]
|
0.914#
|
|
NLR
|
3.32 [2.11,4.60]
|
3.27 [1.75,4.56]
|
0.803#
|
|
LDH, U/L
|
191 [160,229]
|
188 [164,237]
|
0.566#
|
|
CEA, ng/ml
|
5.10 [1.94,32.71]
|
5.23 [1.81,36.86]
|
0.925#
|
|
CYFRA 21-1, ng/ml
|
5.14 [3.33,7.93]
|
5.50 [3.33,8.98]
|
0.413#
|
|
SCC, ng/ml
|
1.10 [0.85,1.63]
|
1.08 [0.82,1.75]
|
0.745#
|
|
Micropaticals at baseline, events/μL, median(IQR)
| | | |
|
total MPs
|
2632 [1942,3600]
|
2586 [1311,3490]
|
0.771#
|
|
NMPs
|
164 [118,317]
|
217 [121,267]
|
0.836#
|
|
PMPs
|
205 [154,258]
|
174 [143,211]
|
0.951#
|
